

Anti-Siglec-2/CD22 Antibody (Epratuzumab)

Introduction

Epratuzumab (Antibody hLL 2) is an anti-CD22IgG1 Monoclonal antibody. Epratuzumab is also a tumor imaging agent and immunomodulator. Epratuzumab can induce CD22 Phosphorylation. Epratuzumab has been studied in non-Hodgkin lymphoma and some autoimmune diseases.

Product parameters

Alternative Names	Lymphocide, AMG 412, hLL2
Target Accession	P20273
Target	Siglec-2 / CD22
CAS number	205923-57-5
Molecular Weight	146.58 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4SP
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

